Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - tetanus toxoid, diphtheria toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, adsorbed aluminium phosphate - suspension for injection - pertussis, purified antigen, combinations with toxoids

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - poliovirus; pertussis toxoid; pertussis filamentous haemagglutinin; diphtheria toxoid; pertactin; tetanus toxoid -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - pertussis filamentous haemagglutinin, quantity: 10 microgram/ml; pertussis fimbriae 2 + 3, quantity: 10 microgram/ml; tetanus toxoid, quantity: 80 iu/ml; pertussis toxoid, quantity: 20 microgram/ml; diphtheria toxoid, quantity: 60 iu/ml; pertactin, quantity: 6 microgram/ml - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; phenoxyethanol - tripacel is indciated for primary immunisation against diphtheria, tetanus and pertussis when commenced between 2 months and 12 months of age. tripacel is also indicated for the fourth and fifth dose for children from 15 months of age up to their eighth birthday who have been immunised previously with three or four doses of diphtheria, tetanus and pertussis (whole cell or acellular) vaccines.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - diphtheria toxoid; tetanus toxoid; pertussis toxoid; filamentous haemagglutinin (fha); pertactin - suspension for injection in pre-filled syringe - 1 dose(s) - pertussis, purified antigen, combinations with toxoids

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - diphtheria toxoid; tetanus toxoid; pertussis toxoid; filamentous haemagglutinin (fha); pertactin; type 1 (mahoney); type 2 (mef-1); type 3 (saukett) - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - diphtheria-pertussis-poliomyelitis-tetanus

Μάλτα - Αγγλικά - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - diphtheria toxoid, tetanus toxoid, bordetella pertussis, pertussis toxoid, filamentous haemagglutinin, fha, pertactin, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate - powder for suspension for injection - diphtheria toxoid 30 iu tetanus toxoid 40 iu bordetella pertussis 30 iu pertussis toxoid 25 µg filamentous haemagglutinin (fha) 25 µg pertactin 8 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg - vaccines

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - pertussis toxoid (pt); filamentous haemagglutinin (fha); pertactin (prn); diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis virus,type 1; inactivated poliomyelitis virus,type 2; inactivated poliomyelitis virus,type 3; fimbriae types 2 and 3 (fim) -

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - diphtheria toxoid, adsorbed 2 [iu] (2.5lfu); pertactin 2.5ug; pertussis filamentous haemagglutinin 8ug; pertussis toxoid, adsorbed 8ug; polio virus type 1 40 dagu; polio virus type 2 8 dagu; polio virus type 3 32 dagu; tetanus toxoid 20 [iu] (5lfu) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (2.5lfu) pertactin 2.5ug pertussis filamentous haemagglutinin 8ug pertussis toxoid, adsorbed 8ug polio virus type 1 40 dagu polio virus type 2 8 dagu polio virus type 3 32 dagu tetanus toxoid 20 [iu] (5lfu) excipient: aluminium medium 199 sodium chloride water for injection - boostrix®-ipv is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of four years onwards. boostrix®-ipv is not intended for primary immunisation.

Καναδάς - Αγγλικά - Health Canada

sanofi pasteur limited - pertactin; fimbriae; filamentous haemagglutinin; pertussis toxoid; tetanus protein; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; haemophilus influenzae type b-prp; tetanus toxoid; diphtheria toxoid - suspension - 3mcg; 5mcg; 20mcg; 20mcg; 30mcg; 26unit; 7unit; 29unit; 10mcg; 5lf; 15lf - pertactin 3mcg; fimbriae 5mcg; filamentous haemagglutinin 20mcg; pertussis toxoid 20mcg; tetanus protein 30mcg; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; haemophilus influenzae type b-prp 10mcg; tetanus toxoid 5lf; diphtheria toxoid 15lf

Ισραήλ - Αγγλικά - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - suspension for injection - tetanus toxoid 5 lf / 1 doses; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses - diphtheria-pertussis-poliomyelitis-tetanus - active booster immunization against diphtheria, tetanus and pertussis in children, adolescents and adults aged 4 to 64 years. adacel is not indicated for treating diseases caused by b.pertussis, c.diphtheriae or c. tetani infections.